A detailed history of Black Rock Inc. transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 11,742,449 shares of TSHA stock, worth $26.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,742,449
Previous 2,597,303 352.1%
Holding current value
$26.9 Million
Previous $7.45 Million 252.87%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$2.04 - $4.17 $18.7 Million - $38.1 Million
9,145,146 Added 352.1%
11,742,449 $26.3 Million
Q1 2024

May 10, 2024

SELL
$1.43 - $3.25 $145,767 - $331,288
-101,935 Reduced 3.78%
2,597,303 $7.45 Million
Q4 2023

Feb 13, 2024

BUY
$1.33 - $2.88 $2.6 Million - $5.62 Million
1,951,170 Added 260.83%
2,699,238 $4.78 Million
Q3 2023

Nov 13, 2023

BUY
$0.63 - $3.66 $269,037 - $1.56 Million
427,043 Added 133.02%
748,068 $2.36 Million
Q2 2023

Aug 11, 2023

SELL
$0.59 - $0.87 $45,111 - $66,520
-76,460 Reduced 19.24%
321,025 $211,000
Q1 2023

May 12, 2023

SELL
$0.65 - $2.3 $205,771 - $728,115
-316,572 Reduced 44.33%
397,485 $317,000
Q4 2022

Feb 13, 2023

SELL
$1.39 - $2.98 $447,012 - $958,344
-321,592 Reduced 31.05%
714,057 $1.61 Million
Q3 2022

Nov 14, 2022

SELL
$1.76 - $4.94 $19,080 - $53,554
-10,841 Reduced 1.04%
1,035,649 $2 Million
Q2 2022

Aug 12, 2022

SELL
$2.47 - $6.77 $2.83 Million - $7.77 Million
-1,147,213 Reduced 52.3%
1,046,490 $3.89 Million
Q1 2022

May 12, 2022

SELL
$5.22 - $11.86 $4.38 Million - $9.95 Million
-839,260 Reduced 27.67%
2,193,703 $14.3 Million
Q4 2021

Feb 10, 2022

BUY
$11.43 - $19.2 $125,661 - $211,084
10,994 Added 0.36%
3,032,963 $35.3 Million
Q3 2021

Nov 09, 2021

BUY
$15.82 - $21.57 $873,232 - $1.19 Million
55,198 Added 1.86%
3,021,969 $56.3 Million
Q2 2021

Aug 11, 2021

BUY
$19.29 - $26.38 $57.2 Million - $78.3 Million
2,966,771 New
2,966,771 $62.9 Million

Others Institutions Holding TSHA

About Taysha Gene Therapies, Inc.


  • Ticker TSHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,359,500
  • Market Cap $111M
  • Description
  • Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...
More about TSHA
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.